Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: comparative study between the Republic of Ireland and Northern Ireland
To investigate the impact of different PSA testing policies and health-care systems on prostate cancer incidence and mortality in two countries with similar populations, the Republic of Ireland (RoI) and Northern Ireland (NI).
Population-level data on PSA tests, prostate biopsies and prostate cancer cases 1993–2005 and prostate cancer deaths 1979–2006 were compiled. Annual percentage change (APC) was estimated by joinpoint regression.
Prostate cancer rates were similar in both areas in 1994 but increased rapidly in RoI compared to NI. The PSA testing rate increased sharply in RoI (APC = +23.3%), and to a lesser degree in NI (APC = +9.7%) to reach 412 and 177 tests per 1,000 men in 2004, respectively. Prostatic biopsy rates rose in both countries, but were twofold higher in RoI. Cancer incidence rates rose significantly, mirroring biopsy trends, in both countries reaching 440 per 100,000 men in RoI in 2004 compared to 294 in NI. Median age at diagnosis was lower in RoI (71 years) compared to NI (73 years) (p < 0.01) and decreased significantly over time in both countries. Mortality rates declined from 1995 in both countries (APC = −1.5% in RoI, −1.3% in NI) at a time when PSA testing was not widespread.
Prostatic biopsy rates, rather than PSA testing per se, were the main driver of prostate cancer incidence. Because mortality decreases started before screening became widespread in RoI, and mortality remained low in NI, PSA testing is unlikely to be the explanation for declining mortality.
KeywordsProstate cancer Trends PSA tests Incidence Mortality
Annual percentage change
National Cancer Registry Ireland
Northern Ireland Cancer Registry
Republic of Ireland
We are grateful to the staff of the Northern Ireland Cancer Registry and the National Cancer Registry Ireland who collected and processed the cancer registration data used in this paper. In particular, we thank Mr Colin Fox, Ms Wendy Hamill and Mr Richard Middleton for their help in providing the data from NI and Christine Buicke for reviewing death certificates in the RoI. We are also grateful to colleagues at HIPE, VHI Healthcare and BUPA for providing biopsy data, and staff in hospitals and laboratories for providing PSA data.
Competing interest statement
All authors declare that the answer to the questions on your competing interest form are all no and therefore have nothing to declare.
Details of contributors
AEC did the statistical analyses. FD collected and provided data on biopsies and PSA tests in the RoI. AB provided the data on PSA tests in NI. PL helped with prostate cancer grade and stage data collection in NI. DC provided the biopsy data in NI. FD, AB, LS, LM, PA, MB, HC and AG took part in the study design. AEC, FD, LS, PA, LE, HC, AG wrote and revised the article. All authors were involved in revisions and approved the final version. AEC is the guarantor for the study.
The Northern Ireland Cancer Registry is funded by the Public Health Agency Northern Ireland, and the National Cancer Registry of Ireland is funded by the Department of Health and Children (Republic of Ireland). Some aspects of the data collection for this study were funded by a grant from the Northern Ireland Research & Development Office and the Health Research Board (Dublin) [grant number NS/2004/20]. The study funders had no role in the study design, the collection, analysis and interpretation of the data. All authors were independent from the funding source.
- 6.Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC et al (1999) Cancer surveillance series: interpreting trends in prostate cancer—part 1: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91(12):1017–1024CrossRefPubMedGoogle Scholar
- 8.Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF (1999) Cancer surveillance series: interpreting trends in prostate cancer—part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 91(12):1033–1039CrossRefPubMedGoogle Scholar
- 14.Drummond FJ, Sharp L, Comber H (2008) Major inter-laboratory variations in PSA testing practices: results from national surveys in Ireland in 2006 and 2007. Ir J Med SciGoogle Scholar
- 15.NHS Cancer Screening Programmes. Prostate Cancer Risk Management. Available at http://www.cancerscreening.nhs.uk/prostate/index.html
- 20.Anderson RN, Minino AM, Hoyert DL, Rosenberg HM (2001) Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. Natl Vital Stat Rep 49(2):1–32Google Scholar
- 21.Central Statistic Office Ireland. Available at http://www.cso.i.e
- 23.Joinpoint regression program (version 3). National Cancer Institute. Available at http://srab.cancer.gov/joinpoint/
- 27.Drummond FJ, Carsin AE, Sharp L, Deady S, Cronin-Fenton DP, Comber H (2007) Treatment of prostate cancer in the real world: population-based practices, factors associated with treatment receipt and impact on survival. J Epidemiol Commun Health 61(Suppl I):A21Google Scholar
- 28.Gavin A, Hughes J, Ranaghan L, Fitzpatrick D. Cancer services audit 1996 & 2001, prostate. N. Ireland Cancer Registry; 2005Google Scholar
- 29.Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 18:CD006019Google Scholar
- 31.NicAmhlaoibh R, Mahmud S, Comber H (2004) Patterns of care and survival from cancer in Ireland 1994 to 1998. National Cancer Registry, CorkGoogle Scholar
- 38.Connolly D (2007) Long term follow-up of men with elevated prostate specific antigen levels: a population based study. MD thesis, Queen’s University Belfast, BelfastGoogle Scholar
- 41.Eichler K, Wilby J, Hempel S, Myers L, Kleijnen J (2005) Diagnostic value of systematic prostate biopsy methods in the investigation for prostate cancer: a systematic review. Centre for Reviews and Dissemination, York, July 2005. Report No: 29Google Scholar
- 43.Health in the European Union. September 2007. Report No.: Special Eurobarometer 272Google Scholar